Bgn-KO mice exhibit reduced bone mass and impaired osteoblast maturation, leading to osteopenia and fractures .
Embryonic Development: Single-cell RNA sequencing revealed fewer mature osteoblasts in Bgn-KO embryos at E16.5, disrupting skeletal cell differentiation .
Fracture Healing: Bgn-KO mice form smaller calluses with fewer chondrocytes but resolve fractures faster due to accelerated remodeling .
Glycosaminoglycan (GAG) Levels:
Bgn-KO mice develop spontaneous aortic dissection (82% thoracic, 18% abdominal) due to collagen fibril disorganization in the aortic adventitia .
Collagen Fibril Defects: Irregular fibril size/shape reduce aortic tensile strength (↓30% maximum load in KO vs. wild-type) .
Elastin Stability: Despite BGN’s association with elastin microfibrils, no structural elastin defects were observed .
Biglycan acts as a danger-associated molecular pattern (DAMP), activating TLR2/4 and enhancing TNF-α/MIP-2 production .
Sepsis Survival: Bgn-KO mice survive longer post-LPS challenge (127 ± 39 hours vs. 20 ± 2 hours in wild-type) .
Macrophage Signaling: BGN induces p38/ERK/NF-κB pathways in macrophages, amplifying inflammation .
Bgn deficiency mitigates fructose-induced cognitive impairment in mice.
Biglycan, abbreviated as BGN, is a small leucine-rich proteoglycan found in the extracellular matrix. Its primary function involves the assembly of collagen fibrils, which are essential structural components of various tissues. Additionally, BGN plays a significant role in muscle regeneration. The structure of BGN shares similarities with two other small proteoglycans, decorin and fibromodulin. Notably, BGN interacts with several proteins implicated in muscular dystrophy. These interactions include those with alpha-dystroglycan, alpha- and gamma-sarcoglycan, and collagen VI. Moreover, BGN is crucial for the proper assembly of the dystrophin-associated protein complex, which is vital for maintaining the structural integrity of muscle fibers.
Recombinant BGN, expressed in Sf9 insect cells, is a single, glycosylated polypeptide chain. This protein comprises 574 amino acids, specifically spanning from amino acid positions 38 to 369. It has a molecular mass of 64.6 kDa. However, on SDS-PAGE analysis, the apparent molecular size will appear between 50-70 kDa. The recombinant BGN is engineered to carry a 242 amino acid long hIgG-His-tag at its C-terminus. Purification of the protein is achieved using proprietary chromatographic techniques.
The product appears as a clear and colorless solution that has been sterilized by filtration.
The BGN solution is provided at a concentration of 0.5 mg/ml. It is formulated in Phosphate Buffered Saline (PBS) with a pH of 7.4 and contains 10% glycerol.
For short-term storage (2-4 weeks), the BGN solution should be kept at 4°C. For extended storage, it is recommended to store the solution at -20°C. Adding a carrier protein like HSA or BSA (0.1%) to the solution before freezing can enhance its long-term stability. Repeated freeze-thaw cycles should be avoided.
The purity of the BGN protein is greater than 90%, as determined by SDS-PAGE analysis.
BGN, DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A, Biglycan, Bone/cartilage proteoglycan I, Biglycan Proteoglycan, MRLS.
Sf9, Insect cells.
ADPDEEASGS DTTSGVPDLD SVTPTFSAMC PFGCHCHLRV VQCSDLGLKT VPKEISPDTT LLDLQNNDIS ELRKDDFKGL QHLYALVLVN NKISKIHEKA FSPLRKLQKL YISKNHLVEI PPNLPSSLVE LRIHDNRIRK VPKGVFSGLR NMNCIEMGGN PLENSGFEPG AFDGLKLNYL
RISEAKLTGI PKDLPETLNE LHLDHNKIQA IELEDLLRYS KLYRLGLGHN QIRMIENGSL SFLPTLRELH LDNNKLSRVP AGLPDLKLLQ VVYLHSNNIT KVGINDFCPM GFGVKRAYYN GISLFNNPVP YWEVQPATFR CVTDRLAIQF GNYKKLEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGKHH HHHH.
A BGN mouse model is a genetically modified mouse with a deficiency or knockout of the biglycan (Bgn) gene. Biglycan is a small leucine-rich repeat proteoglycan (SLRP) that plays crucial roles in extracellular matrix organization across multiple tissues. These mouse models are significant because they allow researchers to study the physiological functions of biglycan in vivo and understand how its absence affects various biological systems, from bone formation to intervertebral disc maintenance and even metabolic regulation .
BGN-deficient mice are generated through targeted disruption of the Bgn gene, typically by inserting a knockout construct into exon 2. Validation of the knockout is performed through genotyping using PCR with specific primers that distinguish between wild-type (approximately 200-bp fragment) and mutant (approximately 300-bp fragment) alleles. The primers typically used are: Bgn forward 5′-CAGGAACATTGACCATG-3′, reverse 5′-GAAAGGACACATGGCACTGAA-3′ and Pgk1 reverse 5′-TGGATGTGGAATGTGTGCGAG-3′ . Additionally, quantitative real-time PCR (qPCR) is employed to confirm the absence of full-length Bgn transcript in knockout animals using primers targeting exon 2: Forward 5′-TGTGGCTACTCACCTTGCTG-3′, Reverse 5′-AGGACACATGGCACTGAAGG-3′ .
BGN-deficient mice exhibit several distinct phenotypic characteristics compared to wild-type counterparts:
Bone structure: Decreased trabecular bone mass and reduced bound water content
Intervertebral discs: Progressive decreases in nucleus pulposus area with age, representative of accelerated disc degeneration
Cell morphology: Changes in cell shape from fibroblastic elongated cells to small rounded cells resembling chondrocytes in the annulus fibrosus
Tissue mechanics: Reduced fracture toughness and altered mechanical properties in bone
The phenotypic changes in BGN-deficient mice follow a progressive timeline:
4 months: Early signs of degeneration in the inner annulus fibrosus; new bone formation in the cartilaginous end plate
6 months: Evident degenerative changes in intervertebral discs; early loss of notochordal cells associated with proliferation of chondrocyte-like cells
9 months: Advanced degenerative changes in the nucleus pulposus and annulus fibrosus; significantly reduced nucleus pulposus size compared to age-matched wild-type mice (BGN-deficient: 0.13 ± 0.098mm² vs. wild-type: 0.2 ± 0.045mm²)
BGN deficiency impacts bone structure and properties in several significant ways:
Bone mass: Bgn deficiency decreases trabecular bone mass, with more pronounced bone loss in double knockout (Bgn/Dcn) mice
Water retention: Marked decrease in bound water content, especially in Bgn KO and double KO mice, as measured by low-field nuclear magnetic resonance
Mechanical properties: Reduced fracture toughness compared to Dcn KO mice
Matrix properties: High resolution atomic force microscopy reveals decreased in situ permanent energy dissipation and increased elastic modulus in the extrafibrillar matrix of Bgn-deficient mice, which were diminished upon dehydration
Signaling pathways: Bgn is indispensable for the activation of ERK and p38 MAPK signaling pathways
BGN plays a critical role in maintaining intervertebral disc integrity:
Structural integrity: BGN deficiency significantly accelerates disc degeneration, suggesting its importance in maintaining disc structural integrity
Cellular changes: BGN-deficient mice exhibit early loss of notochordal cells with proliferation of chondrocyte-like cells, increased cell density, and cell death in the nucleus pulposus and annulus fibrosus
Tissue degradation: Tears, clefts, and mucous degeneration are more abundant in BGN-deficient mice compared to wild-type mice
Boundary maintenance: Boundaries between the nucleus pulposus and inner annulus fibrosus become less distinct in BGN-deficient mice
Research suggests BGN may mediate the effects of fructose on the brain, establishing a potential link between metabolic dysfunction and brain disorders. Studies using BGN knockout mice with and without fructose supplementation in drinking water (15% w/v) examine changes in body composition, glucose tolerance, and cognitive function using behavioral tests like the Barnes Maze . This indicates BGN may be involved in pathways connecting metabolic regulation with neurological function, though more detailed mechanisms require further investigation.
The most effective histological techniques for studying BGN-deficient tissues include:
Classification system: The Boos et al. classification system has been applied effectively to evaluate mice discs, performing histological grading separately for nucleus pulposus/annulus fibrosus and end plate
Histological markers: Assessment of key markers including:
Morphometrical analysis: Quantitative measurement of nucleus pulposus area to track degenerative changes over time
While specific breeding strategies are not detailed in the provided search results, general practices for BGN mouse colonies include:
Genotyping: Regular genotyping using PCR with the specified primers to identify wild-type, heterozygous, and knockout animals
Housing conditions: Group housing at 22–24°C with a 12-hour light/dark cycle
Monitoring: Regular assessment of body composition (using NMR) and metabolic parameters (using intraperitoneal glucose tolerance tests)
Diet considerations: Standard chow with careful control of water intake, especially when studying metabolic effects
Researchers should consider several factors when interpreting seemingly contradictory findings:
Compensatory mechanisms: Dcn is significantly upregulated in Bgn KO mice, while Bgn shows modest upregulation in Dcn KO mice, indicating potential compensatory mechanisms that may confound interpretation of single knockout results
Age-dependent effects: The progression of phenotypic changes can vary significantly with age. For example, nucleus pulposus size differences between wild-type and BGN-deficient mice become statistically significant only at 9 months of age
Tissue-specific effects: BGN deficiency may have different, sometimes opposing effects in different tissues. In bone metabolism studies, BGN-deficient mice showed decreased bone mineral density (BMD) with age, which is opposite to observations in humans where advanced intervertebral disc degeneration is associated with higher BMD
Important limitations to consider include:
Incomplete disease modeling: BGN-deficient mice may not fully recapitulate the later stages of human diseases, such as the absence of subchondral sclerosis and osteophytes formation seen in human spondylosis
Timeframe constraints: Longer-term observation beyond 9 months may be necessary to observe complete disease progression and more advanced degenerative changes
Strain-specific effects: Genetic background could influence the phenotypic manifestations of BGN deficiency, requiring careful consideration when comparing results across studies
Sex differences: The studies primarily used male mice, potentially missing sex-specific effects of BGN deficiency
Emerging research directions include:
Combination studies: Investigating the combined effects of BGN deficiency with other proteoglycan deficiencies, as demonstrated by the double knockout (Bgn/Dcn) models
Therapeutic interventions: Testing potential therapeutic approaches to mitigate accelerated degeneration in BGN-deficient mice
Metabolic-neurological connections: Further exploring the role of BGN in connecting metabolic dysfunction with brain disorders through mechanistic studies
Aging research: Using BGN-deficient mice as models of accelerated aging in tissues like intervertebral discs
Advanced technologies that could enhance BGN mouse research include:
In vivo imaging: Longitudinal tracking of degenerative changes using MRI techniques, similar to those used in rabbit models of disc degeneration
High-resolution atomic force microscopy: Further application to characterize nanomechanical properties of tissues in BGN-deficient mice
Transcriptomics and proteomics: Comprehensive analysis of gene and protein expression changes in multiple tissues of BGN-deficient mice to identify broader pathway alterations
CRISPR-Cas9 technologies: Development of conditional and tissue-specific BGN knockout models to better isolate the effects of BGN deficiency in specific systems
Biglycan is composed of a core protein with leucine-rich repeats (LRRs) flanked by N-terminal and C-terminal cysteine-rich domains . The core protein is approximately 42 kDa in size and contains one or two glycosaminoglycan (GAG) side chains . These GAG chains are typically chondroitin sulfate or dermatan sulfate and are attached to the N-terminus of the core protein .
Biglycan is involved in various biological processes, including:
Recombinant mouse biglycan is used in various research areas, including: